Praxis Precision Medicines
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Praxis Precision Medicines
- Company name
- Praxis Precision Medicines
- Organisation type
- Industry
- Registered legal name
- Praxis Precision Medicines, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001689548
Related records
Trials (17)
- A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
- A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder
- A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
- A Clinical Trial of PRAX-114 in Participants With Essential Tremor
- A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
- A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
- A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628
- A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy
- An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
- Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
- Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
- Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
- Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures